GlassScriptPhysician profile
Michael J Bolger
NPI 1043325970
$513.91
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $34.33 · 2021: $40.84 · 2022: $80.76 · 2023: $17.80 · 2024: $13.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $69.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $47.08 | 2019-2021 | |
| Emd Serono, INC. | $40.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $35.90 | 2019-2022 | |
| Verastem, INC. | $33.21 | 2019 | |
| Pfizer INC. | $32.99 | 2019-2020 | |
| Abbvie INC. | $30.86 | 2021-2022 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Eisai INC. | $25.90 | 2019-2020 | |
| Mylan Institutional INC. | $25.17 | 2019 | |
| Kyowa Kirin, INC. | $22.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.80 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2019 | |
| Janssen Biotech, INC. | $16.31 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.24 | 2019 | |
| Genentech USA, INC. | $14.14 | 2019 | |
| Merck Sharp & Dohme LLC | $13.80 | 2019 | |
| Array Biopharma INC | $13.41 | 2024 | Mektovi, Braftovi, Xalkori |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bolger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.